Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALK-depot SQ 510 Milbenmischung
- Development stage
- Phase 3
- Lead developer
- ALK Abelló
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
ALK-depot SQ 510 Milbenmischung is a subcutaneous allergen immunotherapy (SCIT) product developed by ALK-Abelló. It consists of a standardized mixture of purified natural allergens from two house dust mite species, *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, in equal proportions. The allergens are adsorbed onto aluminum hydroxide, which acts as an adjuvant to provide a depot effect, allowing for gradual release and prolonged immune stimulation. The product is indicated for the treatment of IgE-mediated house dust mite allergy and has been investigated in Phase 3 clinical trials for the treatment of atopic dermatitis in adults with proven sensitization to house dust mites. The therapy involves a dose-escalation phase followed by a maintenance phase, aiming to induce immunological tolerance and reduce allergic symptoms.
- Brand names
- ALK-depot SQ 510 MilbenmischungALK-depot SQ
- Other names
- house dust mite allergen extractDermatophagoides pteronyssinus and Dermatophagoides farinae allergen extractMilbenmischung 510Milbenmischung510Milbenmischung-510ALK-depot SQ house dust mite mixture
02
Targets
HDM-specific IgE (House dust mite-specific immunoglobulin E)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on ALK-depot SQ 510 Milbenmischung.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALK-depot SQ 510 Milbenmischung.